Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...

Left: UMAP projections of CD8⁺/WPRE⁺ (adoptive T cells) and CD8⁺/WPRE⁻ (endogenous T cells) cells mapped onto a reference TIL atlas reveal a reduced prevalence of exhausted CD8⁺ T cells and enrichment ...

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as quickly, making people more susceptible to a variety of infections. To try to ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...